Drugs / Trastuzumab
Trastuzumab
also known as
Herceptin · Herzuma · CT-P6 · Herceptin (trastuzumab) · NSC-688097 · TX05 · Aryogen Trastuzumab · AryoTrust · +15 more
Monoclonal antibody targets ERBB2
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PHESGO | — | 2024-11-22 | fda.gov ↗ |
| Label expansions (8) | US (FDA) | HERCEPTIN | — | 2001-12-11 – 2024-06-18 | fda.gov ↗ |
| Label expansion | US (FDA) | HERZUMA | — | 2019-05-16 | fda.gov ↗ |
| Approved | EU (EMA) | Herceptin | — | 2000-08-28 | europa.eu ↗ |
| Approved | US (FDA) | HERCEPTIN | — | 1998-09-25 | fda.gov ↗ |
Trials 687 · started per year
today
US approved 1998
EU approved 2000
1
5
18
16
19
14
13
14
29
26
30
19
24
16
41
20
30
33
24
20
22
21
28
28
32
37
33
24
28
18
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06098898 | Nov 2023 → Nov 2024 | gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT04958486 | Jul 2021 → Sep 2023 | posterior fossa ependymoma | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03321045 | Nov 2017 → Oct 2028 expected | breast cancer | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 0 | NCT02735798 | Apr 2016 → Jun 2017 | metastatic malignant neoplasm in the brain | Pamela Munster | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT00949247 | Dec 2009 → Jan 2013 | breast cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 168 trials · 4 met primary | ||||||
| Phase 1 | NCT07216105 | Nov 2025 → Jan 2028 expected | breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma +2 | Fate Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05733689 | Jun 2025 → Jun 2027 expected | gastroesophageal adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT05553522 | Jan 2024 → Dec 2025 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Baptist Health South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06886659 | Jan → Dec 2024 | breast cancer | Incepta Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06162559 | Dec 2023 → Aug 2026 overdue | breast cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05187182 | Jun 2023 → Jul 2028 expected | esophageal cancer, gastric cancer, gastroesophageal cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05378464 | May 2022 → Aug 2026 | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05395052 | May 2022 → Aug 2023 | breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer +3 | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05275010 | May 2022 → May 2023 | — | Hoffmann-La Roche | Completed | Met primary |
| Phase 1 | NCT05385705 | May 2022 → Jul 2024 | breast neoplasm | Vall d'Hebron Institute of Oncology | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05143970 | Jan 2022 → Mar 2027 expected | breast cancer, endometrial cancer, esophageal cancer, gastric cancer +4 | Institut Paoli-Calmettes | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05069935 | Oct 2021 → Aug 2023 | cancer | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03846583 | Jun → Sep 2020 | breast cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04367090 | May 2020 → Aug 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03716180 | Nov 2018 → Oct 2020 overdue | breast cancer | Dana-Farber Cancer Institute | Active not recruiting | Met primary |
| Phase 1 | NCT03448042 | Jun 2018 → Nov 2027 expected | cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03432741 | Mar 2018 → Aug 2022 | Hodgkins lymphoma, breast adenocarcinoma, mycosis fungoides, nodal marginal zone B-cell lymphoma | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03319459 | Jan 2018 → May 2020 | HER2 positive breast carcinoma, colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 | Fate Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03364348 | Oct 2017 → Feb 2021 | HER2 positive breast carcinoma | George W. Sledge Jr. | Completed | No outcome recorded |
| Phase 1 | NCT05765357 | Jul → Oct 2017 | breast cancer, gastric cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02774421 | Jun 2017 → Feb 2025 | posterior fossa ependymoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02598427 | May 2017 → Feb 2018 | HER2 positive breast carcinoma | Kimberly Blackwell | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03013218 | Feb 2017 → Feb 2022 | metastatic malignant neoplasm, non-Hodgkin lymphoma | ALX Oncology Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02738970 | Jun 2016 → May 2018 | female breast carcinoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 1 | NCT02705859 | Apr 2016 → May 2021 | HER2 positive breast carcinoma | Cancer Trials Ireland | Completed | No outcome recorded |
| Phase 1 | NCT02605915 | Dec 2015 → Nov 2019 | HER2 positive breast carcinoma, female breast carcinoma, triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02627274 | Dec 2015 → Nov 2022 | breast cancer, head and neck cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02571530 | Aug 2015 → Jun 2021 | metastatic neoplasm | Northwell Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02390427 | Apr 2015 → Dec 2022 | breast carcinoma | Nancy Lin, MD | Completed | No outcome recorded |
| Phase 1 | NCT02152943 | Jul 2014 → Dec 2020 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02167854 | Jun 2014 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02075073 | Feb → Apr 2014 | — | Samsung Bioepis Co., Ltd. | Completed | Met primary |
| Phase 1 | NCT02025192 | Dec 2013 → Oct 2017 | HER2 positive breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01969643 | Oct 2013 → Feb 2023 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01602406 | Sep 2012 → Aug 2017 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01705340 | Sep 2012 → May 2013 | HER2 positive breast carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01649271 | Jul 2012 → Jun 2016 | breast cancer, gastric neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01471847 | Feb → Jun 2012 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01434303 | Jan 2012 → Feb 2016 | HER2 positive breast carcinoma, invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01454804 | Oct 2011 → Mar 2015 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01432886 | Oct 2011 → Aug 2013 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01300962 | Aug 2011 → Feb 2017 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01351350 | Feb 2011 → Sep 2017 | hematopoietic and lymphoid cell neoplasm, high grade malignant neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01285466 | Jan 2011 → Oct 2014 | cancer of unknown primary site | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01097460 | Apr 2010 → Jul 2013 | breast neoplasm | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00960960 | Aug 2009 → Dec 2015 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00927589 | Jul 2009 → Feb 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00928330 | Jul 2009 → Jan 2014 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00811993 | Feb 2009 → Dec 2012 | neoplasm | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT00800436 | Nov 2008 → Oct 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00543504 | Oct 2007 → Apr 2020 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00426556 | Jul 2007 → Mar 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00470847 | Apr 2007 → Dec 2009 | breast cancer, metastatic malignant neoplasm in the brain | Nancy Lin, MD | Completed | No outcome recorded |
| Phase 1 | NCT00367250 | Jul 2006 → Jun 2011 | breast cancer | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 1 | NCT00803556 | Jan 2006 → Aug 2009 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00251433 | Sep 2005 → Jun 2010 | breast neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00199212 | Oct 2003 → Dec 2007 | breast carcinoma | Jules Bordet Institute | Completed | No outcome recorded |
| Phase 1 | NCT00068757 | Aug 2003 → Nov 2007 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1 | NCT00039455 | Apr 2002 → Dec 2004 | HER2 positive breast carcinoma, male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00028535 | Nov 2001 → Feb 2009 | endometrial carcinoma, gastric cancer, male breast carcinoma, malignant epithelial tumor of ovary +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005842 | Jun 2000 → Feb 2004 | cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00014430 | Nov 1999 → Sep 2002 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00004074 | Aug 1999 → Feb 2009 | PPoma, adenoid cystic carcinoma, adrenal cortex carcinoma, anal squamous cell carcinoma +45 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00009997 | Mar 1999 → Jan 2004 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT00002994 | Jul 1997 → Mar 2000 | cancer of unknown primary site | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/265 trials · 1 met primary | ||||||
| Phase 1/2 | NCT06027983 | Nov → Dec 2026 expected | HER2 positive breast carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07136428 | Jul 2026 → Nov 2030 expected | HER2 positive breast carcinoma | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07612215 | May 2026 → May 2029 expected | triple-positive breast carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06686394 | Feb 2025 → Apr 2030 expected | breast cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06572319 | Sep 2024 → Aug 2026 overdue | gastroesophageal junction adenocarcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06650332 | Jul 2024 → Aug 2026 overdue | gastroesophageal cancer | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05785741 | Aug 2023 → Dec 2027 expected | neoplasm | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05749900 | May 2023 → Feb 2026 overdue | — | Yonsei University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05640830 | Jan 2023 → Dec 2025 overdue | carcinoma | Kangbuk Samsung Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05574881 | Sep 2022 → Jan 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05319873 | Apr 2022 → Apr 2027 expected | HER2 positive breast carcinoma, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05091528 | Feb → Jul 2022 | HER2 positive breast carcinoma, non-small cell lung carcinoma | Silverback Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05081609 | Jan 2022 → Aug 2027 expected | HER2 positive breast carcinoma, cervical carcinoma, melanoma, metastatic neoplasm +2 | Ascendis Pharma A/S | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04464967 | Mar 2021 → Aug 2022 | HER2 positive breast carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | NKGen Biotech, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04285671 | Jan 2021 → Dec 2026 expected | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04588545 | Dec 2020 → Apr 2027 expected | HER2 positive breast carcinoma, malignant tumor of meninges | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04152057 | Nov 2019 → Apr 2020 | HER2 positive breast carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04092673 | Oct 2019 → Dec 2024 | cancer | Effector Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT03994107 | Oct 2019 → Jan 2021 | breast cancer | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 1/2 | NCT03368729 | Sep 2019 → Nov 2027 expected | HER2 positive breast carcinoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03913234 | Jun 2019 → Oct 2023 | HER2 positive breast carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03881878 | May 2019 → Oct 2022 | HER2 positive breast carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03101748 | Feb 2018 → May 2025 | inflammatory breast carcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04888663 | Feb 2018 → Sep 2021 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03379428 | Nov 2017 → Jan 2025 overdue | breast cancer | US Oncology Research | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02805829 | Jan 2017 → Jan 2020 | gastric cancer | Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02843126 | Jul 2016 → Jul 2017 | breast carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02657343 | Mar 2016 → Aug 2020 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02393248 | Feb 2015 → Dec 2021 | breast cancer, cholangiocarcinoma, endometrial cancer, gastric cancer +4 | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02318901 | Oct 2014 → Aug 2018 | breast cancer, cancer of unknown primary site, colorectal cancer, esophageal cancer +1 | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02139358 | Sep 2014 → Apr 2018 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02345772 | Jul 2014 → Nov 2015 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02066532 | Jun 2014 → Oct 2020 | HER2 positive breast carcinoma | Dawn L. Hershman | Completed | No outcome recorded |
| Phase 1/2 | NCT02336984 | Jun 2014 → Apr 2016 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02154529 | May 2014 → Sep 2015 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Kadmon Corporation, LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT02030561 | Jan 2014 → Aug 2017 | breast cancer, gastric cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT02120911 | Jan 2014 → Feb 2017 | esophageal cancer | Academic Medical Center - University of Amsterdam | Completed | Met primary |
| Phase 1/2 | NCT01388647 | Aug 2011 → Jun 2014 | HER2 positive breast carcinoma | Vector Oncology | Terminated | No outcome recorded |
| Phase 1/2 | NCT01306942 | Jul 2011 → Dec 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01373710 | May 2011 → Apr 2018 | breast cancer, neoplastic meningitis | Institut Curie | Completed | No outcome recorded |
| Phase 1/2 | NCT01271920 | Sep 2010 → Oct 2013 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00788333 | Jul 2009 → Nov 2011 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00923299 | Dec 2008 → Apr 2010 | malignant pancreatic neoplasm | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1/2 | NCT00726180 | Jul 2008 → Jun 2010 | breast cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00450892 | Feb 2007 → Jul 2013 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1/2 | NCT00258349 | Aug 2006 → Aug 2010 | male breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00317720 | Apr 2006 → Feb 2013 | breast cancer, metastatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00331552 | Feb 2006 → Feb 2011 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT00238420 | Jul 2005 → Feb 2014 | urinary bladder carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00216047 | Jan 2005 → Aug 2006 | breast cancer | Hoosier Cancer Research Network | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00337649 | May 2004 → Jul 2007 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00129896 | Jan 2004 → Dec 2008 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00086957 | Jan 2004 → Aug 2015 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00095706 | Jun 2003 → Apr 2007 | breast cancer | Translational Oncology Research International | Completed | No outcome recorded |
| Phase 1/2 | NCT02297230 | Jun 2002 → Dec 2014 | breast cancer | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00031278 | Oct 2001 → Jun 2003 | breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00033514 | Aug 2001 → Dec 2011 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02015676 | Jul 2001 → Sep 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00006123 | Jul 2000 | female breast carcinoma | Beth Israel Deaconess Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00006825 | Jul 2000 → Jul 2004 | breast cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 1/2 | NCT00004925 | Aug 1999 → Aug 2003 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00006108 | Aug 1999 → Sep 2001 | breast cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2420 trials · 15 met primary · 16 missed | ||||||
| Phase 2 | NCT07848633 | Oct 2026 → Dec 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07802418 | Oct 2026 → Jun 2031 expected | malignant pancreatic neoplasm | Herlev Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07795424 | Sep 2026 → Mar 2028 expected | HER2 positive breast carcinoma | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07857226 | Sep 2026 → Jun 2028 expected | breast cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07694986 | Aug 2026 → Aug 2029 expected | breast cancer, neoplastic meningitis | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07565324 | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07000253 | Apr 2026 → Nov 2031 expected | carcinoma of esophagus, gastric adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 2 | NCT07402473 | Mar 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT07647263 | Mar 2026 → Jun 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07393425 | Feb 2026 → Sep 2027 expected | HER2 positive breast carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Show all 420 trials opens the full record — a long page | ||||||
| Phase 2/310 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07366840 | Jan 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05980481 | Aug 2023 → Jul 2025 overdue | gastric cancer | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05786716 | Mar 2023 → Oct 2029 expected | cancer, colorectal neoplasm, gallbladder neoplasm, hematopoietic and lymphoid cell neoplasm +7 | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05722886 | Mar 2023 → Oct 2029 expected | cancer, hematopoietic and lymphoid cell neoplasm | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05002127 | Jan 2022 → May 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04499924 | Mar 2021 → Apr 2024 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03085368 | Mar 2017 → May 2018 | HER2 positive breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02581462 | Jun 2016 → Jul 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | Met primary |
| Phase 2/3 | NCT01413828 | May 2011 → Aug 2016 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 387 trials · 16 met primary · 13 missed | ||||||
| Phase 3 | NCT07683754 | Sep 2026 → Jul 2030 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06876714 | Sep 2025 → Mar 2028 expected | HER2 positive breast carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06992882 | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06731478 | Feb 2025 → Jun 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05615818 | Jul 2024 → Jun 2027 expected | biliary tract neoplasm | UNICANCER | Recruiting | No outcome recorded |
| Phase 3 | NCT06278870 | Sep 2023 → Jun 2031 expected | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07062263 | Jul 2023 → Jul 2029 expected | HER2 positive breast carcinoma, biliary tract cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT05883852 | Jun 2023 → Jul 2031 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05388500 | Dec 2022 → Dec 2030 expected | HER2 positive breast carcinoma | Institut de cancérologie Strasbourg Europe | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05256225 | Nov 2022 → Oct 2027 expected | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05253651 | Oct 2022 → Dec 2027 expected | colorectal neoplasm | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05415215 | Jul 2022 → Nov 2024 | female breast carcinoma, inflammatory breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05188313 | Mar 2022 → Jul 2027 expected | esophageal adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT05113251 | Oct 2021 → Mar 2025 overdue | HER2 positive breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04973319 | Aug 2021 → Aug 2027 expected | breast cancer | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04547907 | Sep 2020 → Dec 2024 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | Met primary |
| Phase 3 | NCT03803553 | Apr 2020 → Dec 2026 expected | metastasis from malignant tumor of colon | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04193059 | Dec 2019 → Jul 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04109391 | Aug 2019 → Dec 2021 | HER2 positive breast carcinoma | Tanvex BioPharma USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03811418 | Jan → Apr 2019 | HER2 positive breast carcinoma, female breast carcinoma | iOMEDICO AG | Withdrawn | No outcome recorded |
| Phase 3 | NCT03556358 | Jun 2018 → Nov 2020 | HER2 positive breast carcinoma | Tanvex BioPharma USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03264547 | Aug 2017 → Dec 2024 | breast cancer | Japan Breast Cancer Research Group | Completed | Met primary |
| Phase 3 | NCT03425656 | Jul 2016 → Mar 2018 | breast cancer | AryoGen Pharmed Co. | Completed | No outcome recorded |
| Phase 3 | NCT02402712 | May 2015 → Feb 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02125344 | Dec 2014 → Nov 2016 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | Missed primary |
| Phase 3 | NCT02194166 | Jul 2014 → Jul 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02131064 | Jun 2014 → Dec 2015 | breast neoplasm | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT02144012 | Jun 2014 → Jan 2016 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02162667 | Jun 2014 → May 2016 | HER2 positive breast carcinoma | Celltrion | Completed | Met primary |
| Phase 3 | NCT01964391 | Feb 2014 → Dec 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02040935 | Feb 2014 → Sep 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02019277 | Dec 2013 → Nov 2016 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01926886 | Nov 2013 → Sep 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01940497 | Nov 2013 → Apr 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01875367 | Sep 2013 → Nov 2016 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT01810393 | Jun 2013 → Jul 2019 | breast cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01785420 | May 2013 → Sep 2026 | HER2 positive breast carcinoma | Dr Rajendra A. Badwe | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01772472 | Apr 2013 → Jul 2018 | breast cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT01764022 | Oct 2012 → Mar 2015 | HER2 positive breast carcinoma | Biocad | Completed | Met primary |
| Phase 3 | NCT01572038 | Jun 2012 → Sep 2019 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01566721 | May 2012 → Mar 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01526369 | Feb 2012 → Nov 2015 | breast cancer | Cancer Trials Ireland | Completed | No outcome recorded |
| Phase 3 | NCT01450696 | Dec 2011 → Feb 2015 | gastric cancer | Hoffmann-La Roche | Terminated | Missed primary |
| Phase 3 | NCT01160211 | May 2011 → Mar 2016 | breast neoplasm | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01196390 | Feb 2011 → Dec 2019 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT01275677 | Feb 2011 → Jul 2017 | HER2 positive breast carcinoma, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT01120184 | Jul 2010 → Sep 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01104571 | Apr 2010 → Aug 2017 | female breast carcinoma | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| Phase 3 | NCT00968968 | Jan 2010 → Feb 2014 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01104935 | Oct 2009 → Oct 2017 | breast cancer | Comprehensive Support Project for Oncology Research | Completed | Missed primary |
| Phase 3 | NCT00950300 | Oct 2009 → Jul 2011 | breast cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT00770809 | Feb 2009 → Jan 2014 | male breast carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT00769379 | Dec 2008 → Dec 2019 | ductal breast carcinoma in situ | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT01917578 | Aug 2008 → Mar 2014 | breast cancer | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00553358 | Jan 2008 → May 2010 | breast neoplasm | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00629278 | Dec 2007 → Dec 2010 | breast cancer | University Hospital of Modena | Unknown | Missed primary |
| Phase 3 | NCT00637325 | Nov 2007 → May 2009 | breast cancer | Regione Lombardia | Unknown | No outcome recorded |
| Phase 3 | NCT00712140 | Oct 2007 → Oct 2011 | breast cancer | Warwick Medical School | Unknown | Met primary |
| Phase 3 | NCT00567554 | Oct 2007 → Aug 2011 | breast cancer | GBG Forschungs GmbH | Completed | Mixed |
| Phase 3 | NCT00486668 | Jul 2007 → Jun 2012 | invasive breast carcinoma | NSABP Foundation Inc | Unknown | No outcome recorded |
| Phase 3 | NCT00513292 | Jul 2007 → Jun 2012 | HER2 positive breast carcinoma, female breast carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT00490139 | May 2007 → Dec 2013 | breast neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00448279 | Apr 2007 → Sep 2010 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00381901 | May 2006 → May 2011 | breast cancer | National Cancer Institute, France | Completed | Missed primary |
| Phase 3 | NCT00272987 | Dec 2005 → Jul 2009 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00320385 | Nov 2005 → Jun 2007 | breast cancer | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01041404 | Sep 2005 → Jun 2010 | gastric cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT00430001 | May 2005 → Dec 2008 | breast cancer | Danish Breast Cancer Cooperative Group | Unknown | No outcome recorded |
| Phase 3 | NCT00288002 | Jan 2005 → ? | breast cancer | GBG Forschungs GmbH | Completed | Missed primary |
| Phase 3 | NCT00103233 | Dec 2004 → Apr 2006 | breast cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00615602 | Oct 2004 → May 2012 | female breast carcinoma | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00148876 | Sep 2003 → Jan 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00440622 | Apr 2003 → Nov 2008 | breast cancer | Hellenic Oncology Research Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01998906 | May 2002 → Jul 2012 | breast cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT00045032 | Nov 2001 → Mar 2005 | breast cancer | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT00054587 | Jun 2001 → Jun 2009 | breast cancer | UNICANCER | Completed | Missed primary |
| Phase 3 | NCT00016276 | May 2001 → Mar 2005 | female breast carcinoma, inflammatory breast carcinoma, poisoning | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00038402 | Apr 2001 → Nov 2004 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00021255 | Apr 2001 → Dec 2014 | breast neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00022672 | Jan 2001 → Oct 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00005970 | May 2000 → Apr 2005 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 3 | NCT00004067 | Feb 2000 → Mar 2005 | breast cancer | NSABP Foundation Inc | Completed | Met primary |
| Phase 3 | NCT02721641 | Jun 1999 → Feb 2015 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00003440 | Jul 1998 → Jul 2004 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00053339 | — | female breast carcinoma | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07695259 | May 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Wen-Ming Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06217185 | Jan 2024 → Dec 2025 overdue | HER2 positive breast carcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04928261 | Dec 2021 → Dec 2025 overdue | breast cancer | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05036005 | Jul 2021 → Apr 2023 | HER2 positive breast carcinoma, female breast carcinoma | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT02419742 | Aug 2015 → Jun 2021 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02380131 | Feb 2013 → Dec 2017 | gastroesophageal adenocarcinoma | Hebei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01260194 | Jun 2011 → Jan 2015 | gastric cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT01301729 | Mar 2011 → Jul 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00127933 | Aug 2005 → Apr 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00171847 | Mar 2003 → Oct 2008 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07589972 | Apr 2026 → Dec 2027 expected | breast carcinoma by gene expression profile | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07187752 | Sep 2025 → Dec 2026 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT07095023 | Aug 2025 → Dec 2026 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT06854523 | Apr 2025 → Dec 2026 expected | acute myocardial infarction | Yun Dai Chen | Not yet recruiting | No outcome recorded |
| — | NCT06035679 | Aug 2023 → Nov 2026 expected | female breast carcinoma | Youzhi Zhu | Recruiting | No outcome recorded |
| — | NCT05656079 | Jul 2021 → Sep 2024 | breast cancer | Shanghai Pudong Hospital | Unknown | No outcome recorded |
| — | NCT06907082 | Dec 2020 → Mar 2024 | breast cancer | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Completed | No outcome recorded |
| — | NCT03947242 | Jun 2019 → Jun 2020 | HER2 positive breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03847818 | Mar 2019 → Mar 2020 | HER2 positive breast carcinoma | Shandong University | Unknown | No outcome recorded |
| — | NCT02563925 | Sep 2015 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT02102438 | Apr 2014 → Apr 2016 | HER2 positive breast carcinoma | Cancer Institute of the State of São Paulo | Withdrawn | No outcome recorded Stop: Business |
| — | NCT01897441 | Jun 2013 → Oct 2023 | female breast carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01295086 | Mar 2011 → Nov 2014 | adenocarcinoma | Odense University Hospital | Completed | No outcome recorded |
| — | NCT01048099 | Jan 2011 → Jul 2014 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| — | NCT00535509 | Jun 2007 → Jun 2013 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00896376 | Dec 2005 → Dec 2009 | breast cancer | Centre Antoine Lacassagne | Completed | No outcome recorded |
| — | NCT00496808 | Mar 2005 → Nov 2010 | ductal breast carcinoma in situ | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04395508 | — | HER2 positive breast carcinoma | Genentech, Inc. | Approved for marketing | No outcome recorded |
| — | NCT04220203 | — | HER2 positive breast carcinoma | Pfizer | Approved for marketing | No outcome recorded |
| Comparator or background therapy343 trials | ||||||
| Phase 0 | NCT03387553 Background | Jun 2018 → Aug 2023 | HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT01875666 Comparator | Aug 2013 → Dec 2016 | breast neoplasm | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT06687928 Comparator | Mar → Aug 2025 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT06770296 Background | Nov 2024 → Nov 2026 expected | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT06625775 Background | Oct 2024 → Nov 2028 expected | HER2 positive breast carcinoma, colorectal cancer, hormone receptor-positive breast cancer, lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Show all 343 trials opens the full record — a long page | ||||||
Press releases naming this drug 216 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 1,037 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab | “Patients with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy for LR/MBC were stratified by prior adjuvant trastuzumab, prior...” PMID 23569311 ↗ Apr 2013960“Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line...” NCT06450314 ↗ “This first-in-human study with SB3 was designed to evaluate the pharmacokinetic (PK) equivalence between SB3 and trastuzumab sourced in the European Union (EU trastuzumab),...” PMID 27368117 ↗ Jun 2016 “In this study, the investigators plan multicenter phase II clinical trial to test the efficacy, safety and immunogenicity of trastuzumab biosimilar, Herzuma® in combination...” NCT03755141 ↗ “In patients with ER-positive and HER2-positive breast cancer, the therapeutic potential of combining trastuzumab, pertuzumab, and pyrotinib-representing a triple-targeted...” NCT07290166 ↗ “IAM1363 monotherapy OR IAM1363 in combination with capecitabine + trastuzumab OR IAM1363 in combination with capecitabine + zanidatamab OR IAM1363 in combination with T-Dxd OR...” NCT06253871 ↗ “Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion...” NCT01269346 ↗ “Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous), trastuzumab (6 mg/kg on day 1 of each cycle...” PMID 41713473 ↗ Feb 2026 “Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy...” NCT02563925 ↗ “Phase I/II Clinical Study of the Combination of Disitamab Vedotin and Trastuzumab in the Treatment of HER2 Positive Gastric/Gastroesophageal Junction Tumors With Previous...” NCT06572319 ↗ “Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer” PMID 42150145 ↗ May 2026 |
| Known as | Aryogen Trastuzumab | “A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of AryoTrust (AryoGen Trastuzumab) Efficacy and Safety in...” NCT03425656 ↗ |
| Known as | AryoTrust | “Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer” NCT03425656 ↗ |
| Known as | CT-P6 | “Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.” NCT06907082 ↗ |
| Known as | FDC of Pertuzumab and Trastuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03493854 ↗ |
| Known as | H SC | “BACKGROUND: This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC)...” PMID 30018134 ↗ Jul 2018 |
| Known as | Hanquyou | “Trastuzumab (Hanquyou): on the first day of the 21 day cycle, the initial dose was 8mg/kg” NCT05969184 ↗ |
| Known as | Her | “Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy” NCT00004935 ↗ |
| Known as | Herceptin | “The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated...” PMID 23569311 ↗ Apr 2013176“This randomized, open-label, parallel, 2-arm, multicenter study will compare the administration of Herceptin (trastuzumab) with a single-use injection device versus a handheld...” NCT01344863 ↗ “Arm I (control arm, 12-month therapy): Patients continue to receive trastuzumab (Herceptin®) IV until a total of 12 months of therapy is completed in the absence of disease...” NCT00381901 ↗ “A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent...” NCT00258349 ↗ “Trastuzumab for injection is a biosimilar of Herceptin ® produced by Chia Tai Tianqing Biotechnology Co., LTD, which is a humanized IgG1 monoclonal antibody produced by chinese...” NCT05765357 ↗ “One is called trastuzumab (Herceptin®) and it is commonly given to women with early HER2 positive breast cancer or with advanced HER2 positive breast cancer that has spread to...” NCT01276041 ↗ “A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing...” NCT00146549 ↗ “The purpose of the study is to investigate the effects (good and bad) that the combination of the drugs letrozole (also called Femara™) and trastuzumab (also called Herceptin®)...” NCT00134680 ↗ “A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive...” NCT00950300 ↗ “The drug, docetaxel, is combined with another drug, trastuzumab (Herceptin), because at this time this combination appears to be promising in metastatic breast cancer research.” NCT00146042 ↗ “Prospective Randomised Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated With Trastuzumab (Herceptin®) for Metastatic Breast Cancer” NCT00639366 ↗ |
| Known as | Herceptin (trastuzumab) | “Herceptin® (trastuzumab)” NCT00365365 ↗1“Herceptin (trastuzumab)” NCT00412412 ↗ |
| Known as | Herzuma | “D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle)...” NCT03614364 ↗4“Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.” NCT06907082 ↗ “Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1” NCT04722133 ↗ |
| Known as | NSC-688097 | “Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗1“Trastuzumab (Herceptin®) (NSC-688097)” NCT00103233 ↗ |
| Known as | Ontruzant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05036005 ↗ |
| Known as | QL1701 | “QL1701 (Trastuzumab for Injection): First dose 8mg/kg, then 6mg/kg, every 3 weeks, for a total of 6 cycles” NCT07299890 ↗ |
| Known as | QL1701 (A trastuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd) | “QL1701 (A trastuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd)” NCT07187752 ↗ |
| Known as | RhuMab HER2 | “Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression” NCT00003995 ↗ |
| Known as | Tmab | “Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast...” PMID 32381018 ↗ May 2020 |
| Known as | Tras | “Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg...” NCT02393248 ↗ |
| Known as | trastuzumab (Herceptine) | “trastuzumab (Herceptine)” NCT02059876 ↗ |
| Known as | Trastuzumab (T) | “Trastuzumab (T)” NCT03262935 ↗ |
| Known as | Trastuzumab SC | “Trastuzumab SC is a subcutaneous form of trastuzumab.” NCT04893109 ↗ |
| Known as | trastuzumab-EU | “This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU),...” PMID 30568294 ↗ Dec 2018 |
| Known as | TRZ | “trastuzumab reference product (TRZ)” PMID 29448072 ↗ Feb 2018 |
| Known as | TX05 | “This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in...” NCT03556358 ↗1“TX05 (trastuzumab)” NCT04109391 ↗ |
| Action | Deplete | “Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.” NCT00004163 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.” NCT00003440 ↗ |
| Route | Intravenous | “Given IV” NCT00003440 ↗ |
| Target | ERBB2 | “HER-2/neu, the target of trastuzumab” PMID 14981103 ↗ Feb 2004 |